Company News
Kardigan Files US IPO to Fund Heart Drugs
Kardigan, a clinical‑stage biotechnology firm, filed for a U.S. IPO on Nasdaq Global Market under ticker symbol KARD.
The IPO proceeds will fund development of three late‑stage experimental therapies
